Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Enzymopenic hereditary methemoglobinemia.

E R Jaffé

    Haematologia
    |December 1, 1982
    PubMed
    Summary

    Hereditary methemoglobinemia results from rare genetic defects in NADH cytochrome b5 reductase, an enzyme crucial for converting methemoglobin to hemoglobin. Type I is benign, while Type II is a severe, generalized disorder.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Blood and air pollution: state of knowledge and research needs.

    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery·1996
    Same author

    Impact of the environment on blood and blood-forming tissues.

    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery·1993
    Same author

    Commentary: the evolution of the American and International Societies of Hematology: a brief history.

    American journal of hematology·1992
    Same author

    Chronic nonspherocytic hemolytic anemia and G6PD deficiency.

    Hospital practice (Office ed.)·1991
    Same author

    Enzymopenic hereditary methemoglobinemia: a clinical/biochemical classification.

    Blood cells·1986
    Same author

    Methemoglobinemia in the differential diagnosis of cyanosis.

    Hospital practice (Office ed.)·1985

    Area of Science:

    • Biochemistry
    • Genetics
    • Hematology

    Background:

    • Erythrocytes possess a system to convert methemoglobin to hemoglobin.
    • The primary mechanism involves soluble cytochrome b5/NADH cytochrome b5 reductase in the cytosol.
    • This enzyme is derived from microsomal proteins during erythrocyte precursor maturation.

    Purpose of the Study:

    • To describe the genetic basis and clinical manifestations of hereditary methemoglobinemia.
    • To differentiate between Type I and Type II hereditary methemoglobinemia.
    • To discuss diagnostic and therapeutic considerations.

    Main Methods:

    • Analysis of the NADH cytochrome b5 reductase gene on human chromosome 22.
    • Characterization of enzyme activity and stability in affected individuals.
    • Clinical observation and assessment of treatment responses.

    Main Results:

    • Inheritance of abnormal alleles leads to enzymopenic hereditary methemoglobinemia.
    • Type I methemoglobinemia results from mutations affecting enzyme solubility or stability, is benign, and treatable.
    • Type II methemoglobinemia involves a generalized enzyme defect, is severe, and currently untreatable, though prenatal diagnosis is possible.

    Conclusions:

    • NADH cytochrome b5 reductase gene mutations cause hereditary methemoglobinemia.
    • Type I is a treatable cosmetic or mild condition, while Type II is a severe, generalized disorder.
    • Prenatal diagnosis for Type II is feasible, but treatment remains a challenge.

    Related Experiment Videos